FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000821800> ?p ?o ?g. }

• W2000821800 endingPage "898" @default.
• W2000821800 startingPage "892" @default.
• W2000821800 abstract "BackgroundEGFR gene mutation is independently associated with a favorable response in non–small-cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor -tyrosine kinase inhibitors (EGFR-TKIs), regardless of sex or smoking history. Squamous cell carcinoma patients harboring EGFR mutations show a significantly worse response to EGFR-TKIs compared with adenocarcinoma patients. We hypothesized that the serum cytokeratin 19 fragment (CYFRA 21-1) is associated with the efficacy of EGFR-TKIs in EGFR-mutated NSCLC patients.MethodsWe retrospectively screened 160 NSCLC patients harboring EGFR mutations, who had received either gefitinib, or erlotinib between 1992 and 2011. Patients were screened for clinical characteristics, the efficacy of EGFR-TKI, and tumor markers (carcinoembryonic antigen [CEA]/CYFRA 21-1) at the initial diagnosis.ResultsOf 160 eligible patients treated with EGFR-TKIs, 77 patients with high CYFRA 21-1 level (>2 ng/ml) showed significantly shorter progression-free survival (PFS) than the 83 patients with normal CYFRA 21-1 level (median PFS, 7.5 versus 13.3 months; p < 0.001). No significant difference in PFS was observed between the high-CEA group (>5 ng/ml) and the normal-CEA group (median PFS, 8.6 versus 11.2 months; p = 0.242). A multivariate analysis revealed that high CYFRA 21-1 level is independently associated with PFS (hazard ratio, 1.27; p = 0.002). No significant difference in overall survival was observed between the high- and the normal-CYFRA 21-1 groups (median overall survival, 24.8 versus 39.1 months; p = 0.104).ConclusionsPatients with a high CYFRA 21-1 level have significantly shorter PFS. CYFRA 21-1 is not a prognostic but a predictive marker of EGFR-TKI treatment in EGFR-mutated NSCLC patients. EGFR gene mutation is independently associated with a favorable response in non–small-cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor -tyrosine kinase inhibitors (EGFR-TKIs), regardless of sex or smoking history. Squamous cell carcinoma patients harboring EGFR mutations show a significantly worse response to EGFR-TKIs compared with adenocarcinoma patients. We hypothesized that the serum cytokeratin 19 fragment (CYFRA 21-1) is associated with the efficacy of EGFR-TKIs in EGFR-mutated NSCLC patients. We retrospectively screened 160 NSCLC patients harboring EGFR mutations, who had received either gefitinib, or erlotinib between 1992 and 2011. Patients were screened for clinical characteristics, the efficacy of EGFR-TKI, and tumor markers (carcinoembryonic antigen [CEA]/CYFRA 21-1) at the initial diagnosis. Of 160 eligible patients treated with EGFR-TKIs, 77 patients with high CYFRA 21-1 level (>2 ng/ml) showed significantly shorter progression-free survival (PFS) than the 83 patients with normal CYFRA 21-1 level (median PFS, 7.5 versus 13.3 months; p < 0.001). No significant difference in PFS was observed between the high-CEA group (>5 ng/ml) and the normal-CEA group (median PFS, 8.6 versus 11.2 months; p = 0.242). A multivariate analysis revealed that high CYFRA 21-1 level is independently associated with PFS (hazard ratio, 1.27; p = 0.002). No significant difference in overall survival was observed between the high- and the normal-CYFRA 21-1 groups (median overall survival, 24.8 versus 39.1 months; p = 0.104). Patients with a high CYFRA 21-1 level have significantly shorter PFS. CYFRA 21-1 is not a prognostic but a predictive marker of EGFR-TKI treatment in EGFR-mutated NSCLC patients." @default.
• W2000821800 created "2016-06-24" @default.
• W2000821800 creator A5000653374 @default.
• W2000821800 creator A5002327424 @default.
• W2000821800 creator A5004396112 @default.
• W2000821800 creator A5006122700 @default.
• W2000821800 creator A5016131935 @default.
• W2000821800 creator A5022022857 @default.
• W2000821800 creator A5022846980 @default.
• W2000821800 creator A5024943202 @default.
• W2000821800 creator A5031993878 @default.
• W2000821800 creator A5032826078 @default.
• W2000821800 creator A5036577393 @default.
• W2000821800 creator A5044227853 @default.
• W2000821800 creator A5058673085 @default.
• W2000821800 creator A5062454590 @default.
• W2000821800 creator A5079280347 @default.
• W2000821800 creator A5080938148 @default.
• W2000821800 creator A5081905843 @default.
• W2000821800 creator A5090494204 @default.
• W2000821800 date "2013-07-01" @default.
• W2000821800 modified "2023-10-04" @default.
• W2000821800 title "Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR Mutation" @default.
• W2000821800 cites W1896982762 @default.
• W2000821800 cites W1969875009 @default.
• W2000821800 cites W1978756244 @default.
• W2000821800 cites W1988442083 @default.
• W2000821800 cites W2002960454 @default.
• W2000821800 cites W2007602495 @default.
• W2000821800 cites W2016693266 @default.
• W2000821800 cites W2025404610 @default.
• W2000821800 cites W2038397881 @default.
• W2000821800 cites W2043696829 @default.
• W2000821800 cites W2045728965 @default.
• W2000821800 cites W2056365691 @default.
• W2000821800 cites W2056659899 @default.
• W2000821800 cites W2069810305 @default.
• W2000821800 cites W2078294783 @default.
• W2000821800 cites W2085400294 @default.
• W2000821800 cites W2088039296 @default.
• W2000821800 cites W2095618958 @default.
• W2000821800 cites W2099725888 @default.
• W2000821800 cites W2104748005 @default.
• W2000821800 cites W2112621029 @default.
• W2000821800 cites W2114642822 @default.
• W2000821800 cites W2118135682 @default.
• W2000821800 cites W2125195105 @default.
• W2000821800 cites W2132157071 @default.
• W2000821800 cites W2138297714 @default.
• W2000821800 cites W2139939379 @default.
• W2000821800 cites W2140459856 @default.
• W2000821800 cites W2143859186 @default.
• W2000821800 cites W2148538574 @default.
• W2000821800 cites W2161821474 @default.
• W2000821800 cites W2166084034 @default.
• W2000821800 cites W2590141690 @default.
• W2000821800 doi "https://doi.org/10.1097/jto.0b013e31828c3929" @default.
• W2000821800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23591159" @default.
• W2000821800 hasPublicationYear "2013" @default.
• W2000821800 type Work @default.
• W2000821800 sameAs 2000821800 @default.
• W2000821800 citedByCount "36" @default.
• W2000821800 countsByYear W20008218002013 @default.
• W2000821800 countsByYear W20008218002014 @default.
• W2000821800 countsByYear W20008218002015 @default.
• W2000821800 countsByYear W20008218002016 @default.
• W2000821800 countsByYear W20008218002017 @default.
• W2000821800 countsByYear W20008218002018 @default.
• W2000821800 countsByYear W20008218002019 @default.
• W2000821800 countsByYear W20008218002021 @default.
• W2000821800 countsByYear W20008218002023 @default.
• W2000821800 crossrefType "journal-article" @default.
• W2000821800 hasAuthorship W2000821800A5000653374 @default.
• W2000821800 hasAuthorship W2000821800A5002327424 @default.
• W2000821800 hasAuthorship W2000821800A5004396112 @default.
• W2000821800 hasAuthorship W2000821800A5006122700 @default.
• W2000821800 hasAuthorship W2000821800A5016131935 @default.
• W2000821800 hasAuthorship W2000821800A5022022857 @default.
• W2000821800 hasAuthorship W2000821800A5022846980 @default.
• W2000821800 hasAuthorship W2000821800A5024943202 @default.
• W2000821800 hasAuthorship W2000821800A5031993878 @default.
• W2000821800 hasAuthorship W2000821800A5032826078 @default.
• W2000821800 hasAuthorship W2000821800A5036577393 @default.
• W2000821800 hasAuthorship W2000821800A5044227853 @default.
• W2000821800 hasAuthorship W2000821800A5058673085 @default.
• W2000821800 hasAuthorship W2000821800A5062454590 @default.
• W2000821800 hasAuthorship W2000821800A5079280347 @default.
• W2000821800 hasAuthorship W2000821800A5080938148 @default.
• W2000821800 hasAuthorship W2000821800A5081905843 @default.
• W2000821800 hasAuthorship W2000821800A5090494204 @default.
• W2000821800 hasBestOaLocation W20008218001 @default.
• W2000821800 hasConcept C121608353 @default.
• W2000821800 hasConcept C126322002 @default.
• W2000821800 hasConcept C143998085 @default.
• W2000821800 hasConcept C170493617 @default.
• W2000821800 hasConcept C207103383 @default.
• W2000821800 hasConcept C2776256026 @default.
• W2000821800 hasConcept C2776362946 @default.

• next